Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth

KRAS is the most frequently mutated oncogene in human tumors, and its activating mutations represent important therapeutic targets. The combination of Cas9 and guide RNA from the CRISPR-Cas system recognizes a specific DNA sequence and makes a double-strand break, which enables editing of the releva...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Genome Res
Asıl Yazarlar: Kim, Wonjoo, Lee, Sangeun, Kim, Han Sang, Song, Minjung, Cha, Yong Hoon, Kim, Young-Hoon, Shin, Jeonghong, Lee, Eun-Seo, Joo, Yeonsoo, Song, Jae J., Choi, Eun Ju, Choi, Jae W., Lee, Jinu, Kang, Moonkyung, Yook, Jong In, Lee, Min Goo, Kim, Yeon-Soo, Paik, Soonmyung, Kim, Hyongbum (Henry)
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Cold Spring Harbor Laboratory Press 2018
Konular:
Method
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5848616/
https://ncbi.nlm.nih.gov/pubmed/29326299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gr.223891.117
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller